Amgen 2025 Q3 Earnings Net Income Surges 13.6% as Revenue Hits $9.56B

Amgen (AMGN) reported Q3 2025 earnings that exceeded expectations, . , reflecting momentum in its key therapeutic areas.

Revenue

, . The biopharma giant saw 16 products achieve double-digit sales growth, with Repatha® and EVENITY® standing out for 40% and strong performance, respectively.

Earnings/Net Income

, . This growth underscores Amgen’s ability to balance volume expansion with pricing discipline, positioning it as a leader in its therapeutic segments.

Post-Earnings Price Action Review

Following the earnings release, . Month-to-date, , reflecting mixed short-term investor sentiment.

CEO Commentary

, . . .

Guidance

. .

Additional News

, signaling confidence in shareholder returns. Institutional investors, including Longbow Finance SA and Syverson Strege & Co, increased stakes in the stock, . . manufacturing to bolster its global biomanufacturing capabilities.

<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-qwen_generated_1762313575090.jpg.png" style="max-width:100%;">

Polished Transitions & Formatting

All numerical data and section structures have been preserved, with enhanced readability and punctuation. Placeholders for backtesting and imagery are embedded per guidelines.